This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
End-To-End Support at Every Stage of Your Drug Development Journey
Brochures, Pharmaceutical, Device Innovations, Brand Differentiation, Product Solutions
Towards A New Standard of Care with Aptar Pharma’s Digital Health
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions
Aptar Pharma discusses an antibody nasal spray for SARS-CoV-2
Publications, Pharmaceutical, Innovation & Insights, Product Solutions
Delivering On The Promises of Intranasal Vaccination
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
